The second author's initials also appear incorrectly in the citation. The correct citation is:
Boon GJAM, van Rein N, Bogaard HJ, Ende-Verhaar YM, Huisman MV, Kroft LJM, et …

Background The pathophysiology of chronic thromboembolic pulmonary hypertension
(CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk …

We would like to thank H. Slabbynck and co-workers for their interest in the 2019 European
Society of Cardiology/European Respiratory Society guidelines on the diagnosis and …

Dear Editor, We welcome the opportunity to reply to Dr Davidson's letter and address his
concerns and questions about our recent review. Regarding the initial selection of …

1. Pawar A, Gagne JJ, Gopalakrishnan C, et al. Association of type of oral anticoagulant
dispensed with adverse clinical outcomes in patients extending anticoagulation therapy …

1. Pawar A, Gagne JJ, Gopalakrishnan C, et al. Association of type of oral anticoagulant
dispensed with adverse clinical outcomes in patients extending anticoagulation therapy …

Pulmonary embolism (PE) is the third most frequent acute cardiovascular syndrome. The PE-
associated mortality and morbidity in Germany and other European countries continues to …

The clinical management of patients with acute pulmonary embolism is rapidly changing
over the years. The widening spectrum of clinical management strategies for these patients …

Why do we not have a precise answer to the question of which patients with pulmonary
embolism (PE), particularly intermediate risk (submassive) PE, ought to receive fibrinolysis …

Within FOCUS, a comprehensive follow-up was programmed for all patients, comprising 18
domains, performed on admission, discharge, and at 3, 6, and 12 months after the event. Of …